Wuxi Biologics Sells Vaccines Ireland Facility for $500M

Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an announcement.

Wuxi Biologics (Cayman) Inc. announced a significant asset transaction involving its Vaccines Ireland Facility, selling it to MSD International for approximately US$500 million. The transaction, classified as a discloseable transaction under the Listing Rules, includes manufacturing equipment and contracts related to the facility, and the company guarantees the vendor’s obligations under the agreement.

More about Wuxi Biologics (Cayman)

Wuxi Biologics (Cayman) Inc. is a company incorporated in the Cayman Islands, operating in the biotechnology industry. The company primarily focuses on the development and manufacturing of biologics, including vaccines, operating facilities like the Vaccines Ireland Facility.

YTD Price Performance: 1.16%

Average Trading Volume: 4,262

Technical Sentiment Consensus Rating: Buy

Current Market Cap: $8.97B

See more insights into 2269 stock on TipRanks’ Stock Analysis page.